WO2012032541A1 - Pseudopolymorphe d'adéfovir dipivoxil - Google Patents

Pseudopolymorphe d'adéfovir dipivoxil Download PDF

Info

Publication number
WO2012032541A1
WO2012032541A1 PCT/IN2011/000608 IN2011000608W WO2012032541A1 WO 2012032541 A1 WO2012032541 A1 WO 2012032541A1 IN 2011000608 W IN2011000608 W IN 2011000608W WO 2012032541 A1 WO2012032541 A1 WO 2012032541A1
Authority
WO
WIPO (PCT)
Prior art keywords
adefovir dipivoxil
formic acid
acid solvate
adefovir
dipivoxil
Prior art date
Application number
PCT/IN2011/000608
Other languages
English (en)
Inventor
Ramakoteswara Rao Jetti
Anjaneyaraju Indukuri
Balakrishna Reddy Bhogala
Satish Beeravelli
Original Assignee
Matrix Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd filed Critical Matrix Laboratories Ltd
Publication of WO2012032541A1 publication Critical patent/WO2012032541A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to a novel pseudopolymorph of Adefovir dipivoxil, and process for the preparation thereof.
  • the present invention specifically relates to Adefovir dipivoxil formic acid solvate.
  • Adefovir dipivoxil is a diester prodrug of adefovir.
  • Adefovir is an orally-administered nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B.
  • Adefovir dipivoxil (9-[2-[ bis[(pivaloyIoxy)methoxy]phosphinyl]- methoxy]ethyl]adenine) having Formula-I is more suitable for developing formulations and has been recommended as a drug.
  • United States patent US 6451340 discloses various crystalline salts of Adefovir dipivoxil. Fumaric acid, hemisulfate, hydrobromide, hydrochloride, nitrate, mesylate, ethyl sulfonate, ⁇ -naphthylene sulfonic acid, a-naphthylene sulfonic acid, (S)-camphor sulfonic acid, succinic acid, maleic acid, ascorbic acid and nicotinic acid salts or complexes disclosed in the US 6451340.
  • United States patent publication US 20090247749 discloses novel salts and cocrystals of Adefovir dipivoxil.
  • Cocrystals of Adefovir dipivoxil with Nicotimamide, salicylamide and saccharin salt of Adefovir dipivoxil are disclosed in the patent publication US '749.
  • WO 2010062147 discloses Ethanolate solvate of Adefovir dipivoxil.
  • Active pharmaceutical ingredients are frequently administered in the solid state as part of an approved dosage type (e.g., tablets, capsules, etc.). Solids provide a convenient, compact and generally a stable format to store an API or a drug product.
  • APIs can exist in a variety of distinct solid forms (solvates or pseudopolymorphs, hydrates and polymorphs), where each form may display unique physicochemical properties such as hygroscopicity, morphology, solubility and bioavailability.
  • solvates or pseudopolymorphs, hydrates and polymorphs may display unique physicochemical properties such as hygroscopicity, morphology, solubility and bioavailability.
  • some potentially useful compounds with highly desirable molecular pharmacological properties may never realize their maximum potential. This is because of the physical properties of the bulk material which may provide unfavorable bioavailability, processing characteristics, and unacceptable shelf-life.
  • Current approaches to changing properties of APIs include the utilization of ionic salts, solvates, hydrates, and polymorphs.
  • the principle object of the present invention is to provide a novel pseudopolymorph of Adefovir dipivoxil.
  • Another object of the present invention is to provide Adefovir dipivoxil formic acid solvate.
  • Another object of the present invention is to provide process for the preparation of Adefovir dipivoxil formic acid solvate.
  • Figure 1 illustrates Powder X-ray diffraction pattern of Adefovir dipivoxil formic acid solvate.
  • Figure 2 illustrates DSC thermogram of Adefovir dipivoxil formic acid solvate.
  • Figure 3 illustrates TGA/DTA of Adefovir dipivoxil formic acid solvate.
  • Figure 4 illustrates Infrared spectrum of Adefovir dipivoxil formic acid solvate.
  • Figure 5 illustrates ⁇ -NMR spectrum of Adefovir dipivoxil formic acid solvate.
  • Figure 6 illustrates thermal ellipsoid plot of Adefovir Dipivoxil formic acid solvate with atomic numbering scheme.
  • Figure 7 illustrates comparison of experimental and simulated (from single crystal data) Powder X-ray diffraction patterns of Adefovir Dipivoxil Formic acid solvate.
  • the present invention relates to a novel pseudopolymorph of Adefovir dipivoxil.
  • the present invention specifically relates to Adefovir dipivoxil formic acid solvate.
  • the present invention further provides process for the preparation of Adefovir Dipivoxil formic acid solvate.
  • the main aspect of the present invention is to provide Adefovir Dipivoxil formic acid solvate.
  • the present invention provides process for the preparation of Adefovir Dipivoxil formic acid solvate comprising the steps of:
  • the ethereal solvent used in step-b is selected from diethyl ether, diisopropyl ether, Methyl tert-butyl ether, preferably diisopropyl ether.
  • Adefovir dipivoxil is dissolved in formic acid at a temperature 15-45 °C preferably 25-35 °C and to the obtained clear solution ethereal solvent is added.
  • Ethereal solvent is selected from diethyl ether, diisopropyl ether, Methyl tert-butyl ether, preferably diisopropyl ether.
  • the obtained solid is filtered, optionally washed with ethereal solvent and Adefovir dipivoxil formic acid solvate is isolated.
  • Adefovir dipivoxil formic acid solvate was monitored by subjecting approximately 1.0 g of the sample to different stress conditions; Drying, exposure to Relative Humidity, milling and Slurry conversion. The samples were tested by PXRD. The novel form is stable to drying at 40°C, 90 % relative humidity and slurry conditions as shown in the following Table 1.
  • Adefovir dipivoxil formic acid was monitored by storing the sample at both long term (25°C and 60% Relative Humidity) and accelerated stability (40°C and 75% Relative Humidity) conditions.
  • the samples were tested by PXRD after 15 days, 1 month, 2 months and 3 months and the observed results were shown below (Table 2).
  • Adefovir dipivoxil formic acid solvate is stable under lab stress conditions (drying, humidity, milling and slurry) as mentioned in Table 1. From indicative stability data it appears that the formic acid solvate is physically and chemically stable up to three months as shown in Table 2.
  • Adefovir dipivoxil anhydrate Form I The physical stability of Adefovir dipivoxil anhydrate Form I was monitored by subjecting approximately 1.0 g of the sample to different stress conditions; Drying, milling and exposure to Relative Humidity (RH). The samples were tested by PXRD and results incorporated in Table 3.
  • Adefovir dipivoxil formic acid solvate and Adefovir dipivoxil Form I were determined in distilled water and at several pH (0.1N HC1, acetate buffer and phosphate buffer) at 25 °C and the results were incorporated in Table 4.
  • Adefovir dipivoxil formic acid solvate is more stable to humidity & milling (Table 1) compared to the Adefovir dipivoxil anhydrate Form I (Table 3).
  • Table 4 The solubility data incorporated in Table 4 shows that Adefovir dipivoxil Formic acid solvate has superior solubility over Adefovir dipivoxil anhydrate Form I.
  • the said formic acid solvate of the present invention is characterized by their X-ray powder diffraction pattern.
  • the X-ray diffraction patterns of said polymorphs of the invention were measured on Bruker AXS D8 Discover powder X-ray diffractometer equipped with a goniometer of ⁇ /2 ⁇ configuration, Variol monochromator and Lynx-Eye detector.
  • the Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 2 ⁇ range of 2.0°-50.0°, 0.030° step size and 25 seconds step time.
  • the DSC measurements were carried out on TA Q1000 of TA instruments. The experiments were performed at a heating rate of 10.0 °C/min over a temperature range of 30°C-200°C purging with nitrogen at a flow rate of 50ml/min. Standard aluminum crucibles covered by lids with three pin holes were used. Thermo gravimetric Analysis (TGA)
  • TGA/DTA was recorded using the instrument TA Q5000 of TA instruments. The experiments were performed at a heating rate of 10.0 °C/min over a temperature range of 30°C-300°C purging with nitrogen at a flow rate of 25ml/min.
  • IR Infrared
  • FT-IR Fourier transform infrared
  • Adefovir dipivoxil formic acid solvate is characterized by the Powder X-ray diffraction having peaks at about 14.08, 16.41, 19.42 and 23.34 ( ⁇ ) 0.2 2 ⁇ values.
  • Adefovir dipivoxil formic acid solvate is further characterized by the Powder X-ray diffraction having peaks at about 7.94, 14.08, 14.48, 16.41 , 17.00 18.64, 19.42, 20.16, 20.97, 21.38, 22.45, 23.34, 23.87, 25.30 and 32.92 ( ⁇ ) 0.2 2 ⁇ values.
  • Adefovir dipivoxil formic acid solvate is further characterized by the Powder X-ray diffraction as depicted in Figure 1.
  • Adefovir dipivoxil formic acid solvate is further characterized by DSC thermogram as depicted in Figure 2.
  • DSC thermogram endothermic peak at 1 16.4 °C shows the melting point of Adefovir dipivoxil formic acid pseudopolymorph.
  • Adefovir dipivoxil formic acid solvate is further characterized by TGA/DTA as depicted in Figure 3.
  • the Adefovir dipivoxil formic acid solvate is further characterized by Infrared spectrum as depicted in Figure 4.
  • the Adefovir dipivoxil formic acid solvate is further characterized by 1 H-NMR spectrum as depicted in Figure 5.
  • Adefovir dipivoxil formic acid solvate is characterized by single crystal X-ray diffraction as shown in Figure 6.
  • the crystallographic data and atomic coordinates are incorporated respectively in Table 5 and Table 6.
  • Table 5 Crystallographic Data of Adefovir Dipivoxil formic acid solvate from single crystal X-ray diffraction.
  • Table 6 Atomic coordinates of Adefovir Dipivoxil formic acid solvate obtained from single crystal X-ray diffraction.
  • Adefovir dipivoxil 5g was dissolved in formic acid (5 mL) at room temperature and stirred for 20 minutes. To the resulting clear solution, 75 ml of diisopropyl ether was added dropwise over a period of 30 minutes under stirring and continued for 4 h. The solid obtained was filtered and washed with 10 mL of diisopropyl ether and dried to yield Adefovir dipivoxil formic acid solvate.
  • Adefovir dipivoxil 5g was dissolved in formic acid (5 mL) at room temperature and stirred for 20 minutes. To the resulting clear solution, 75 ml of Methyl tert-butyl ether was added dropwise over a period of 30 minutes under stirring and continued for 4 h. The solid obtained was filtered and washed with 10 mL of Methyl tert-butyl ether and dried to yield Adefovir dipivoxil formic acid solvate.
  • Adefovir dipivoxil 25g was dissolved in formic acid (25 mL) at room temperature and stirred for 20 minutes. To the resulting clear solution, 375 mL of diisopropyl ether was added dropwise over a period of 30 minutes under stirring and stirring was continued for 4 h. The solid obtained was filtered and washed with 50 mL (2 x 25 mL) of diisopropyl ether to yield 25g of crystalline Adefovir dipivoxil Formic acid solvate. This material was slurred in 125 mL of acetonitrile for 4 h. The material was filtered and dried at 40 °C u/v for 15h to yield 20g of Adefovir dipivoxil formic acid solvate.
  • Adefovir dipivoxil 50g was dissolved in formic acid (40 mL) at room temperature and stirred for 20 minutes. To the resulting clear solution, 500 mL of diisopropyl ether was added dropwise over a period of 30 minutes under stirring and stirring was continued for 3-4 h. The solid obtained was filtered and washed with 100 mL (2 x 50 mL) of diisopropyl ether to yield 50g of crystalline Adefovir dipivoxil Formic acid solvate. This material was slurred in 100 mL of acetone for 2 h. The material was filtered and dried at 40 °C u/v for 15h to yield 47 g of Adefovir dipivoxil formic acid solvate.
  • Adefovir dipivoxil formic acid solvate powder 100 mg was dissolved in MeOH (2 mL) in a conical flask and allowed for slow evaporation at room temperature. Diffraction quality single crystals were obtained in about 2 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau pseudopolymorphe d'adéfovir dipivoxil, et un procédé pour le préparer. La présente invention concerne spécifiquement un solvat d'acide formique d'adéfovir dipivoxil.
PCT/IN2011/000608 2010-09-06 2011-09-06 Pseudopolymorphe d'adéfovir dipivoxil WO2012032541A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2578/CHE/2010 2010-09-06
IN2578CH2010 2010-09-06
IN755/CHE/2011 2011-03-14
IN755CH2011 2011-03-14

Publications (1)

Publication Number Publication Date
WO2012032541A1 true WO2012032541A1 (fr) 2012-03-15

Family

ID=45094048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000608 WO2012032541A1 (fr) 2010-09-06 2011-09-06 Pseudopolymorphe d'adéfovir dipivoxil

Country Status (1)

Country Link
WO (1) WO2012032541A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663159A (en) 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
WO1999004774A2 (fr) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Compositions d'analogue de nucleotide
US20020045599A1 (en) * 1997-07-25 2002-04-18 Gilead Sciences, Inc. Nucleotide analog compositions
US20090247749A1 (en) 2008-03-31 2009-10-01 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2010062147A2 (fr) 2008-11-28 2010-06-03 (주)아모레퍼시픽 Forme cristalline d'adefovir fipivoxil, procédé de préparation associé et composition pharmaceutique contenant cette forme

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663159A (en) 1990-09-14 1997-09-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
WO1999004774A2 (fr) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Compositions d'analogue de nucleotide
US20020045599A1 (en) * 1997-07-25 2002-04-18 Gilead Sciences, Inc. Nucleotide analog compositions
US6451340B1 (en) 1997-07-25 2002-09-17 Gilead Sciences, Inc. Nucleotide analog compositions
US20090247749A1 (en) 2008-03-31 2009-10-01 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
WO2010062147A2 (fr) 2008-11-28 2010-06-03 (주)아모레퍼시픽 Forme cristalline d'adefovir fipivoxil, procédé de préparation associé et composition pharmaceutique contenant cette forme

Similar Documents

Publication Publication Date Title
US10669275B2 (en) Methods of preparing co-crystals of ibrutinib with carboxylic acids
EP2603503B1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
US11149017B2 (en) Solid state forms of apalutamide
WO2017008773A1 (fr) Formes cristallines d'acide obéticholique
US10689380B1 (en) Crystalline forms of valbenazine ditosylate
US11332467B2 (en) Solid state forms of palbociclib dimesylate
US9221815B2 (en) Solid state form of vemurafenib choline salt
EP3743405B1 (fr) Acide fumarique siponimod cristallin et polymorphes de celui-ci
WO2017140283A1 (fr) Solvates d'olaparib cristallin avec l'acétone, le 2-propanol et/ou la méthyléthylcétone
US20190270735A1 (en) Polymorphs of Dasatinib
WO2015085972A1 (fr) Nouveaux sels de 3-(2-imidazo[1,2-b]pyridazin-3-yl-éthynyl)-4-méthyl-n-[4-[(4-méthyl-1-pipérazinyl)méthyl]-3-(trifluorométhyl)phényl]benzamide
WO2012071425A1 (fr) Formes à l'état solide de bésylate de sorafénib et procédés de préparation
WO2012032541A1 (fr) Pseudopolymorphe d'adéfovir dipivoxil
WO2022229026A1 (fr) Forme solide de tafamidis et son procédé de préparation
US11053261B2 (en) Solid state forms of ixazomib citrate
WO2016157136A1 (fr) Formes cristallines de l'idélalisib
US9920045B2 (en) Solid state forms of a PDE10 inhibitor
US11420945B2 (en) Solid state forms of Pemafibrate
JP2020535192A (ja) レナリドミドの結晶形
CZ2016222A3 (cs) Pevné formy solí obeticholové kyseliny
US20240150282A1 (en) Novel crystalline compound of siponimod hemifumarate
WO2016081538A1 (fr) Formes solides de ceritinib et sels de ceux-ci
CZ2017646A3 (cs) Kokrystal (3α,5ß,6α,7α)-6-ethyl-3,7-dihydroxycholan-24-ové kyseliny s kyselinou benzoovou
WO2019047989A2 (fr) FORMES CRISTALLINES D'ACIDE (3α,5β,6α,7α)-6-ÉTHYL-3,7-DIHYDROXYCHOLAN-24-IQUE
WO2021038590A1 (fr) Nouveau polymorphe de succinate de ribociclib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791053

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11791053

Country of ref document: EP

Kind code of ref document: A1